Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
ACS Appl Mater Interfaces ; 8(3): 1780-5, 2016 Jan 27.
Artículo en Inglés | MEDLINE | ID: mdl-26771257

RESUMEN

Partially reduced graphene oxide (prGO) was covalently functionalized with a zwitterionic polymer polyzwitterionic polymer to afford a composite material with excellent dispersibility and long-term stability in high salinity brines including standard API and Arab-D found in deep oil reservoirs. When heated at 90 °C, the dispersions remained stable in excess of 140 days. These results suggest the utility of imidazolium-based polymers for brine stabilization as well as the use of diazonium containing polymers for a "grafting-to" approach to nanocarbon functionalization.

2.
Cardiovasc Pathol ; 22(5): 357-67, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23478013

RESUMEN

BACKGROUND: The possibility of decreasing or reverting left ventricular hypertrophy and, therefore, cardiac hypertrophy (CH) is an important medical issue. The aim of the present study was to evaluate these two possibilities with a 3-week daily dose of captopril, losartan, or bromocriptine in a preventive or corrective model. METHODS: After aorto caval fistulae (ACF) surgery on adult male Wistar rats to induce CH, animals were assigned to the preventive protocol (drug treatment began immediately after surgery) or corrective protocol (hypertrophy was allowed to develop before drug treatment). After treatments, isoproterenol was administered to half of the animals to further induce CH. The groups included the passive control, the sham-operated animals, those with ACF surgery but without drug treatment, and the 3-week treatments with captopril, losartan, or the low or high dose of bromocriptine. RESULTS: Three treatments, with captopril, losartan, or the high dose of bromocriptine, significantly impeded/reverted an increase in CH-related parameters in the preventive/corrective model compared to the surgically treated group without drug treatment. The same effect was found after isoproterenol administration. The present results show an avoidance/reversion of CH with these three treatments. Better results were found with the angiotensin converting enzyme inhibitor (captopril) than with the prolactin inhibitor (bromocriptine). CONCLUSIONS: Treatments with captopril, losartan, and the high dose of bromocriptine were effective in preventing/reversing the manifestation of CH in the preventive/corrective rat models. Further studies are needed to identify the initial mediator, the key component, and the molecular events involved in the pathogenesis of CH.


Asunto(s)
Cardiomegalia/prevención & control , Prolactina/antagonistas & inhibidores , Animales , Enfermedades de la Aorta/complicaciones , Fístula Arteriovenosa/complicaciones , Presión Sanguínea/efectos de los fármacos , Bromocriptina/administración & dosificación , Captopril/administración & dosificación , Cardiomegalia/tratamiento farmacológico , Cardiomegalia/patología , Modelos Animales de Enfermedad , Antagonistas de Hormonas/administración & dosificación , Humanos , Hipertrofia Ventricular Izquierda/tratamiento farmacológico , Hipertrofia Ventricular Izquierda/patología , Hipertrofia Ventricular Izquierda/prevención & control , Losartán/administración & dosificación , Masculino , Ratas , Ratas Wistar , Vena Cava Inferior
3.
Adv Mater ; 25(12): 1739-44, 2013 Mar 25.
Artículo en Inglés | MEDLINE | ID: mdl-23359435

RESUMEN

Copolymers with a triscarbazole hole-transport group and an oxetane or benzocyclobutene crosslinkable group can be readily thermally crosslinked on timescales of 30 min or less, with rapid thermal processing (RTP) being highly effective for this purpose. Devices with RTP-crosslinked hole-transport layers and spin-coated emissive layers exhibit high external quantum efficiencies of up to 15%.


Asunto(s)
Iluminación/instrumentación , Sustancias Luminiscentes/química , Compuestos Orgánicos/química , Temperatura , Silicio/química , Soluciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA